Pigment Cell & Melanoma Research · 2015 · 46 citations · 26 references
MedicineOncologyPharmacologyMetastasisMolecular OncologyTumor ProgressionCancer ProgressionMalignant NeoplasmsMalignant TumorsMetastatic Disease TreatmentTargeted Cancer TherapyTherapeutic ResistanceBraf V600 MutationsCheckpoint Resistance MechanismsKinase Inhibitor ResistanceMelanoma ProgressionMetastatic Melanoma TreatmentPi3k InhibitorsTumor Resistance
Here, we retrospectively review imaging of 68 consecutive unselected patients with BRAF V600-mutant metastatic melanoma for organ-specific response and progression on vemurafenib. Complete or partial responses were less often seen in the central nervous system (CNS) (36%) and bone (16%) compared to lung (89%), subcutaneous (83%), spleen (71%), liver (85%) and lymph nodes/soft tissue (83%), P < 0.001. CNS was also the most common site of progression. Based on this, we tested in vitro the efficacy of the BRAF inhibitors PLX4720 and dabrafenib in the presence of cerebrospinal fluid (CSF). Exogenous CSF dramatically reduced cell death in response to both BRAF inhibitors. Effective cell killing was restored by co-administration of a PI-3 kinase inhibitor. We conclude that the efficacy of vemurafenib is variable in different organs with CNS being particularly prone to resistance. Extrinsic factors, such as ERK- and PI3K-activating factors in CSF, may mediate BRAF inhibitor resistance in the CNS.
26
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Stephanie M. Pyonteck, Leila Akkari, Alberto J. Schuhmacher et al. · Nature Medicine · 2013 · 2.5K citations · Full text
Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
Nathalie Dhomen, Jorge S. Reis‐Filho, Silvy da Rocha Dias et al. · Cancer Cell · 2009 · 578 citations · Full text